Clinical Trial Update: Long-term, Open-label Safety Extension Study of Retigabine/Ezogabine in Pediatric Subjects (>= 12 Years Old) With POS or LGS [Phase 3]

View source ↗

Summary

Phase 3 long-term open-label safety extension for retigabine/ezogabine in pediatric subjects with epilepsy has been terminated; results posted in 2014.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epilepsy

Drugs mentioned

• Ezogabine (ezogabine)
• Retigabine (ezogabine)

Snippet

Sponsor: GlaxoSmithKline | Conditions: Epilepsy | Phase 3 | Status: TERMINATED | Results posted: 2014-08-04